LOST. THE FDA SAYS IT IS NOW REVIEWING THE DATA TO SEE IF ANY ACTIONS, LIKE LABELING CHANGES, ARE NEEDED. THE MAKER OF OZEMPIC AND WEGOVY SAY PATIENT SAFETY IS ITS TOP PRIORITY AND THAT IT IS WORKING CLOSELY WITH.
LOST. THE FDA SAYS IT IS NOW REVIEWING THE DATA TO SEE IF ANY ACTIONS, LIKE LABELING CHANGES, ARE NEEDED. THE MAKER OF OZEMPIC AND WEGOVY SAY PATIENT SAFETY IS ITS TOP PRIORITY AND THAT IT IS WORKING CLOSELY WITH.